NEULANDLAB - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.5
| Stock Code | NEULANDLAB | Market Cap | 19,249 Cr. | Current Price | 15,003 ₹ | High / Low | 19,748 ₹ |
| Stock P/E | 108 | Book Value | 1,257 ₹ | Dividend Yield | 0.08 % | ROCE | 18.7 % |
| ROE | 14.8 % | Face Value | 10.0 ₹ | DMA 50 | 13,879 ₹ | DMA 200 | 13,975 ₹ |
| Chg in FII Hold | -0.44 % | Chg in DII Hold | 1.12 % | PAT Qtr | 40.4 Cr. | PAT Prev Qtr | 96.5 Cr. |
| RSI | 61.0 | MACD | 472 | Volume | 28,184 | Avg Vol 1Wk | 24,983 |
| Low price | 10,578 ₹ | High price | 19,748 ₹ | PEG Ratio | 2.28 | Debt to equity | 0.16 |
| 52w Index | 48.2 % | Qtr Profit Var | -29.2 % | EPS | 139 ₹ | Industry PE | 30.1 |
📊 Financials: NEULANDLAB shows moderate fundamentals with ROE at 14.8% and ROCE at 18.7%. EPS is strong at ₹139, but quarterly PAT declined sharply (₹40.4 Cr vs ₹96.5 Cr), reflecting earnings volatility. Debt-to-equity ratio of 0.16 is manageable, providing stability. Dividend yield of 0.08% is negligible, offering little income support.
💹 Valuation: The stock trades at a P/E of 108, far above the industry average of 30.1, indicating extreme overvaluation. PEG ratio of 2.28 highlights stretched growth expectations. Book value of ₹1,257 provides strong intrinsic support, but valuation multiples remain expensive. RSI at 61.0 suggests momentum but not yet overbought.
🏭 Business Model: NEULANDLAB operates in pharmaceuticals with strengths in niche APIs and specialty products. Its competitive advantage lies in R&D capabilities and global demand. However, high valuations, earnings volatility, and modest profitability growth limit near-term attractiveness.
📈 Entry Zone: Attractive entry would be near ₹14,800–₹15,000, aligning with support levels and fairer valuation. Current price (₹15,003) is above both 50 DMA (₹13,879) and 200 DMA (₹13,975), suggesting bullish momentum but stretched valuations. Long-term investors should accumulate cautiously on dips.
Positive
- Strong EPS of ₹139.
- ROCE (18.7%) and ROE (14.8%) reflect moderate efficiency.
- Debt-to-equity ratio of 0.16 indicates manageable leverage.
- DII holdings increased (+1.12%), showing domestic institutional confidence.
Limitation
- Extremely high P/E (108) vs industry average (30.1).
- PEG ratio of 2.28 indicates stretched valuation.
- Quarterly PAT declined sharply (₹40.4 Cr vs ₹96.5 Cr).
- Dividend yield of 0.08% is negligible.
Company Negative News
- Sharp decline in quarterly profits.
- FII holdings declined (-0.44%), showing reduced foreign confidence.
Company Positive News
- DII inflows (+1.12%) reflect strong domestic support.
- Strong EPS base and manageable debt levels.
Industry
- Pharmaceutical sector remains resilient with global demand.
- Industry P/E at 30.1 highlights NEULANDLAB’s premium valuation.
- Regulatory risks and competition affect margins.
Conclusion
⚖️ NEULANDLAB demonstrates moderate efficiency and strong EPS but trades at extreme valuations with earnings volatility. Entry is favorable near ₹14,800–₹15,000 for cautious long-term investors. Current levels suggest cautious accumulation, with better opportunities on dips. Holding is viable if earnings stabilize, but valuation risks remain elevated.